Clinical trial · Interventional
Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
Functional Liver Imaging With Sulfur Colloid SPECT/CT in Primary and Metastatic Liver Cancer Patients Receiving Liver-Directed Treatment: A Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Terminated due to low accrual in Cohort B. (Accrual goal for Cohort A was met.)
Summary
Brief summary (as posted)
This pilot trial studies how well single photon emission computed tomography (SPECT)/computed tomography (CT) with technetium Tc-99m sulfur colloid works in measuring liver function in patients with liver cancer that has or has not spread to other place in the body who are undergoing radiation therapy or surgery. Diagnostic procedures, such as sulfur colloid SPECT/CT scans, may measure normal liver tissue before, during and after treatment and help doctors plan better treatment for liver cancer patients.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Intrahepatic Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Stage IVA Liver Cancer | Malignant Liver Neoplasm | CURATED_BROADER | 0.78 |
| Stage IVB Liver Cancer | Malignant Liver Neoplasm | CURATED_BROADER | 0.78 |
| Stage IV Liver Cancer | Malignant Liver Neoplasm | CURATED_BROADER | 0.78 |
| Vascular Thrombosis | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Computed Tomography | Procedure | — | UNRESOLVED |
| Single Photon Emission Computed Tomography | Procedure | — | UNRESOLVED |
| Technetium Tc-99m Sulfur Colloid | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (SC SPECT/CT)
- description
- There are 2 cohorts of patients: Those receiving radiation therapy per standard of care (Cohort A) and those undergoing surgery per standard of care (Cohort B). All patients have a total of 3 SPECT/CT imaging with 99mTc-SC. The first scan in both cohorts is routine medical care (not experimental) and takes place prior to initiation of RT or surgery. Two follow up scans are part of the protocol. * In cohort A, the first follow up scan occurs at mid-RT, and the second one at 1 month post-RT. * In cohort B, the first follow-up scan occurs 3-5 days postoperatively, and the second one at 1 month post-operatively. An additional IV contrast enhanced CT scan (70 second delay) will be obtained immediately following the SPECT/CT scan for all 3 SPECT/CT scans.
- interventionNames
- Procedure: Computed Tomography
- Procedure: Single Photon Emission Computed Tomography
- Drug: Technetium Tc-99m Sulfur Colloid
Primary outcomes (4)
- measure
- Longitudinal Changes in Liver Function as Measured by SC SPECT/CT Functional Liver Volume: Cohort A - Radiation
- timeFrame
- Baseline, mid-treatment at 2 weeks, and post-treatment at 1 month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a diagnosis of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma, or metastatic liver cancer planned to receive definitive doses of radiation or surgical resection are eligible * Measurable hepatic disease and/or presence of vascular tumor thrombosis * Diagnostic CT or magnetic resonance imaging (MRI) scan within 2 months of study entry * There are no limits on prior therapy; patients are allowed to have prior systemic therapy, radiation therapy, radiofrequency ablation, catheter-based therapies, and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients unable to tolerate a SPECT/CT 99mTc-SC scan * Patients who are not planning to adhere to the required follow up schedule as outlined in this protocol * Pregnant women * Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception * Patients unable to provide informed consent
References
Publications (0)
Data not yet available